Pasithea Therapeutics (KTTA) Return on Equity (2021 - 2024)
Pasithea Therapeutics (KTTA) has disclosed Return on Equity for 4 consecutive years, with 0.63% as the latest value for Q3 2024.
- Quarterly Return on Equity fell 59.0% to 0.63% in Q3 2024 from the year-ago period, while the trailing twelve-month figure was 0.63% through Sep 2024, down 59.0% year-over-year, with the annual reading at 0.01% for FY2023, 3.0% up from the prior year.
- Return on Equity hit 0.63% in Q3 2024 for Pasithea Therapeutics, down from 0.43% in the prior quarter.
- In the past five years, Return on Equity ranged from a high of 0.01% in Q3 2022 to a low of 0.63% in Q3 2024.
- Historically, Return on Equity has averaged 0.13% across 4 years, with a median of 0.05% in 2022.
- Biggest five-year swings in Return on Equity: grew 3bps in 2023 and later tumbled -59bps in 2024.
- Year by year, Return on Equity stood at 0.06% in 2021, then rose by 21bps to 0.05% in 2022, then surged by 65bps to 0.02% in 2023, then plummeted by -3505bps to 0.63% in 2024.
- Business Quant data shows Return on Equity for KTTA at 0.63% in Q3 2024, 0.43% in Q2 2024, and 0.19% in Q1 2024.